Un-Sustained Response to Benralizumab in Eosinophilic Asthma with Previous 3 Year Mepolizumab Administration

نویسندگان
چکیده

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Treatment response with mepolizumab in severe eosinophilic asthma patients with previous omalizumab treatment

BACKGROUND We performed post hoc analyses to evaluate the effect of humanized monoclonal antibody mepolizumab in patients with severe eosinophilic asthma previously treated with omalizumab. METHODS Data were collected from two randomized double-blind, placebo-controlled studies: MENSA (NCT01691521: 32-week treatment phase) and SIRIUS (NCT01691508: 24-week treatment phase). Active treatment wa...

متن کامل

Mepolizumab in refractory eosinophilic asthma.

In a recent Lung Alert reviewing our study of mepolizumab in severe eosinophilic asthma, Barratt states that the study population represented a minority of patients with asthma and that they had corticosteroidresistant disease. These comments require clarification. While we accept that the population studied by us represents about 3% of the total asthma population, it was 30% of patients with r...

متن کامل

Mepolizumab (Nucala) For Severe Eosinophilic Asthma.

Mepolizumab (Nucala) for severe eosinophilic asthma.

متن کامل

Mepolizumab treatment in patients with severe eosinophilic asthma.

BACKGROUND Some patients with severe asthma have frequent exacerbations associated with persistent eosinophilic inflammation despite continuous treatment with high-dose inhaled glucocorticoids with or without oral glucocorticoids. METHODS In this randomized, double-blind, double-dummy study, we assigned 576 patients with recurrent asthma exacerbations and evidence of eosinophilic inflammation...

متن کامل

Response to case report: Airway autoimmune responses in severe eosinophilic asthma following low-dose Mepolizumab therapy

© The Author(s) 2017. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if c...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Journal of Investigational Allergology and Clinical Immunology

سال: 2020

ISSN: 1018-9068

DOI: 10.18176/jiaci.0652